Fadrozole hydrochloride
SIGMA/F3806 - ≥98% (HPLC)
Synonym: 4-
CAS Number: 102676-31-3
Empirical Formula (Hill Notation): C14H13N3·HCl
Molecular Weight: 259.73
MDL Number: MFCD00866239
Linear Formula: C14H13N3·HCl
Product Type: Chemical
This picture is provided solely for illustration purposes, it may have been created or edited with AI. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts F3806-10MG
| assay | ≥98% (HPLC) |
| form | powder |
| InChI | 1S/C14H13N3.ClH/c15-8-11- |
| InChI key | UKCVAQGKEOJTSR-UHFFFAOYSA |
| originator | Novartis |
| Quality Level | 100  |
| SMILES string | Cl.N#Cc1ccc(cc1)C2CCCc3cn |
| solubility | DMSO: >20 mg/mL |
| storage temp. | room temp |
| Biochem/physiol Actions: | Fadrozole is a nonsteroidal aromatase inhibitor. |
| Biochem/physiol Actions: | Fadrozole is a nonsteroidal aromatase inhibitor. Fadrozole is a very potent and highly selective inhibitor of the aromatase enzyme system in vitro and estrogen biosynthesis in vivo. It inhibited the conversion of [4-14C]androstenedione to [4-14C]estrone by human placental microsomes in a competitive manner (Ki = 1.6 nM). At a substrate concentration 3-fold the Km, Fadrozole was 180 times more potent, as an inhibitor, than aminoglutethimide (Cat. No. A9657), exhibiting half-maximal inhibition at 1.7 nM as compared to 0.3 μM. In vivo, Fadrozole lowered ovarian estrogen synthesis by gonadotropin-primed, androstenedione treated, immature rats by 90% at a dose of 260 μg/kg (PO). In vivo, Fadrozole leads to sequelae of estrogen deprivation (e.g. regression of DMBA-induced mammary tumors) without causing adrenal hypertrophy in adult rats. It blocked aromatase by 50% in human breast cancer homogenates, live breast cancer cells, human placental microsomes, and porcine ovarian microsomes at concentrations of 0.008 to 0.02 μM. |
| Features and Benefits: | This compound was developed by Novartis . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 10, 50 mg in glass bottle |
| Symbol |   GHS06,GHS08 |
| Signal word | Danger |
| Hazard statements | H301 - H361 |
| Precautionary statements | P201 - P202 - P264 - P270 - P280 - P301 + P310 |
| Hazard Codes | Xn |
| Risk Statements | 63-22 |
| Safety Statements | 36/37 |
| RIDADR | UN 2811 6.1 / PGIII |
| WGK Germany | WGK 2 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | room temp |
| UNSPSC | 51111800 |